OTC · Financial Statements
Astellas Pharma Inc. (ALPMY) Financial Statements
$13.13
OTC: ALPMY
Market Cap $23.52B
Overview Financials Dividend Astellas Pharma Inc. most recently reported annual revenue of $2.27T, net profit of $309.1B, revenue has compounded at 12.7% a year over the last five years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2022 2023 2024 2025 2026 Revenue $1.30T $1.52T $1.60T $1.91T $2.27T Operating Profit $155.7B $285.4B $25.5B $41.0B $445.0B Net Profit $124.1B $98.7B $17.0B $50.7B $309.1B EPS $67.05 $54.09 $9.47 $28.24 $172.56 Op Margin 12.0% 18.8% 1.6% 2.1% 19.6%
Balance Sheet (USD)
Metric 2022 2023 2024 2025 2026 Total Assets $2.33T $2.46T $3.57T $3.34T $3.58T Total Liabilities $872.1B $948.6B $1.97T $1.83T $1.74T Cash $316.0B $376.8B $335.7B $188.4B $282.8B Borrowings $212.7B $200.0B $920.0B $831.4B $247.0B
Cash Flow (USD)
Metric 2022 2023 2024 2025 2026 Operating Cash Flow $258.2B $332.3B $172.5B $194.5B $600.4B Investing Cash Flow $-139.6B $-177.6B $-928.3B $-146.7B $-138.4B Financing Cash Flow $-71.1B $-80.3B $-40.5B $-43.9B $-198.2B Net Cash Flow $-10.1B $60.9B $-41.2B $-147.3B $81.6B Free Cash Flow $181.7B $243.8B $90.0B $137.2B $539.2B
Valuation & Return Ratios
Metric Value PEG Ratio 0.03 EV / EBITDA 6.96 FCF Yield 13.22% Quick Ratio 0.90 Interest Coverage 28.77 Return 1Y 36.34% Return 3Y 4.49% Return 5Y -8.64%
Screens featuring this stock